Scholarlink

Background <p>Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by a deficiency of the L-phenylalanine-4-hydroxylase enzyme or its cofactor tetrahydrobiopterin (BH4) resulting in increased levels of phenylalanine (Phe) in blood and cerebrospinal fluid. Symptoms include hypopigmentation, a musty, mouse-like smell and various neurological complications.</p> Main text <p>Treatment options include (i) dietary restriction of Phe with supplementation of other amino acids and micronutrients through medical mixtures, (ii) daily dosing of large neutral amino acids, (iii) synthetic forms of BH4 and (iv) bacterial phenylalanine ammonia lyase enzymes. The primary goal of treatment is to lower blood Phe levels and improve quality of life. However, treatment is very demanding for patients as well as their families, and not all treatment options are applicable to every patient.</p> Conclusion <p>This review gives a state-of-the-art overview of current treatment options for all PKU patients and additionally speculates on future therapeutic approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current state of the treatment landscape of phenylketonuria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Ine Nulmans,
  • Sien Lequeue,
  • Liesbeth Desmet,
  • Jessie Neuckermans,
  • Joery De Kock

摘要

Background

Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by a deficiency of the L-phenylalanine-4-hydroxylase enzyme or its cofactor tetrahydrobiopterin (BH4) resulting in increased levels of phenylalanine (Phe) in blood and cerebrospinal fluid. Symptoms include hypopigmentation, a musty, mouse-like smell and various neurological complications.

Main text

Treatment options include (i) dietary restriction of Phe with supplementation of other amino acids and micronutrients through medical mixtures, (ii) daily dosing of large neutral amino acids, (iii) synthetic forms of BH4 and (iv) bacterial phenylalanine ammonia lyase enzymes. The primary goal of treatment is to lower blood Phe levels and improve quality of life. However, treatment is very demanding for patients as well as their families, and not all treatment options are applicable to every patient.

Conclusion

This review gives a state-of-the-art overview of current treatment options for all PKU patients and additionally speculates on future therapeutic approaches.